Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
Business Wire•06/11/2026•16:00 ET
0
Key Highlights
- ➤Camzyos maintained consistent efficacy and safety through 56 weeks in pediatric symptomatic oHCM patients
- ➤No pediatric patient treated with Camzyos experienced LVEF below 55% through 56 weeks
- ➤Camzyos remains the first approved treatment for pediatric patients ≥30 kg with symptomatic oHCM
- ➤SCOUT-HCM found no new adverse reactions compared with those identified in adult studies
Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions
With a consistent efficacy and safety profile through 56-weeks of follow-up, the Phase 3 SCOUT-HCM clinical trial further reinforces Camzyos as the first approved treatment for pediatric patients ≥30 kg with symptomatic oHCM
Get started
Create a free account to read the full story.